At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 194 target
Drug / intervention
LB1410 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating LB1410 and LB4330 for Solid Tumor. Currently recruiting, targeting 194 participants across 1 site.
Detailed Summary
This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
CollaboratorsShanghai East Hospital
Timeline
Phase 2Recruiting
2025202620272028
Enrollment StartJun 2024
First PostedJun 2024
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedJun 21, 2024
Enrollment StartJun 19, 2024
Primary CompletionDec 30, 2026
Study CompletionDec 30, 2027
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 2.0 years agoPrimary completion in 6 months
Interventions
LB1410drug
anti-PD-1/TIM3 bispecific antibody
LB4330drug
anti-claudin18.2/IL-10 fusion protein